Literature DB >> 1655134

Major orthopaedic surgery on the leg and thromboembolism.

J Parker-Williams, R Vickers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655134      PMCID: PMC1670904          DOI: 10.1136/bmj.303.6802.531

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  18 in total

1.  Influence of skinfold thickness on heparin absorption.

Authors:  C Kroon; A de Boer; J M Kroon; H C Schoemaker; F J van den Meer; A F Cohen; H C Schoenmaker
Journal:  Lancet       Date:  1991-04-20       Impact factor: 79.321

2.  Mobilisation after hip surgery and efficacy of thromboprophylaxis.

Authors:  M R Lassen; L C Borris
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

3.  Orthopaedic surgeons and thromboprophylaxis.

Authors:  M D Laverick; S A Croal; R A Mollan
Journal:  BMJ       Date:  1991-09-07

4.  Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement.

Authors:  W H Harris; E W Salzman; C Athanasoulis; A C Waltman; S Baum; R W DeSanctis
Journal:  J Bone Joint Surg Am       Date:  1974-12       Impact factor: 5.284

5.  Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.

Authors:  P F Leyvraz; J Richard; F Bachmann; G Van Melle; J M Treyvaud; J J Livio; G Candardjis
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

6.  Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo.

Authors:  M R Lassen; L C Borris; H M Christiansen; K L Boll; S P Eiskjaer; B W Nielsen; P Schøtt; A D Olsen; J C Rodenberg; U Lucht
Journal:  Acta Orthop Scand       Date:  1991-02

7.  Efficacy of fixed minidose warfarin prophylaxis in total hip replacement.

Authors:  M J Fordyce; A S Baker; G E Staddon
Journal:  BMJ       Date:  1991-07-27

8.  Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

Authors:  P F Leyvraz; F Bachmann; J Hoek; H R Büller; M Postel; M Samama; M D Vandenbroek
Journal:  BMJ       Date:  1991-09-07

9.  Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding.

Authors:  C W Francis; V J Marder; C M Evarts; S Yaukoolbodi
Journal:  JAMA       Date:  1983-01-21       Impact factor: 56.272

10.  Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.

Authors:  A Planes; N Vochelle; F Mazas; C Mansat; J Zucman; A Landais; J C Pascariello; D Weill; J Butel
Journal:  Thromb Haemost       Date:  1988-12-22       Impact factor: 5.249

View more
  6 in total

1.  Low molecular weight heparin.

Authors:  S Gough
Journal:  BMJ       Date:  1991-09-28

Review 2.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

3.  Current practice in primary total hip replacement: results from the National Hip Replacement Outcome Project.

Authors:  A J Best; D Fender; W M Harper; A W McCaskie; K Oliver; P J Gregg
Journal:  Ann R Coll Surg Engl       Date:  1998-09       Impact factor: 1.891

4.  Audit of thromboembolic prophylaxis in hip and knee surgery.

Authors:  H R Williams; D A Macdonald
Journal:  Ann R Coll Surg Engl       Date:  1997-01       Impact factor: 1.891

5.  Current UK opinion on thromboprophylaxis in orthopaedic surgery: its use in routine total hip and knee arthroplasty.

Authors:  A J Unwin; J R Jones; W J Harries
Journal:  Ann R Coll Surg Engl       Date:  1995-09       Impact factor: 1.891

Review 6.  Postsurgical complications in older patients. The role of pharmacological intervention.

Authors:  G Zuccalà; A Cocchi; G Gambassi; R Bernabei; P Carbonin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.